{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:16:37Z","timestamp":1783430197035,"version":"3.54.6"},"reference-count":61,"publisher":"IMR Press","issue":"3","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Alpha Psychiatry"],"abstract":"<jats:p>\u200b\u200bEight psychiatrists from Malaysia, Singapore, Taiwan, Hong Kong, and Thailand participated in three meetings using the RAND Corporation\/University of California Los Angeles (RAND\/UCLA) appropriateness method to establish expert consensus on the use of lurasidone for bipolar I depression in Asian patients. The first meeting generated clinical questions and statements for voting, the second refined these statements, and the third addressed disagreements or areas of uncertainty. Consensus was defined as \u226566% agreement that a statement was appropriate or extremely appropriate. Nearly all proposed statements achieved consensus, including the use of lurasidone as a first-line treatment for first-episode bipolar I depression in adults, with a starting dose of 20 mg\/day and titration up to 120 mg\/day as needed, as well as its use as adjunctive therapy with mood stabilizers. For elderly patients, a lower dose range of 20\u201380 mg\/day was recommended, while for children and adolescents, a dose range of 20\u201380 mg\/day with careful monitoring was suggested. Lurasidone was considered to have a lower risk of inducing mania or hypomania compared with placebo, conventional antidepressants, and certain antipsychotics, and was associated with a favorable cardiometabolic profile and generally manageable side effects, including nausea, akathisia, and somnolence. Caution was advised when prescribing lurasidone during pregnancy, particularly in the first trimester. This expert consensus provides practical guidance for the use of lurasidone in the treatment of bipolar I depression in Asian patients, complementing existing treatment guidelines and addressing dosing strategies, side effect management, and use in special populations.<\/jats:p>","DOI":"10.31083\/ap49358","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:42:51Z","timestamp":1783428171000},"source":"Crossref","is-referenced-by-count":0,"title":["Expert Consensus on the Use of Lurasidone for Bipolar I Depression in Asian Patients"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8364-4594","authenticated-orcid":true,"given":"Ahmad Hatim","family":"Sulaiman","sequence":"first","affiliation":[{"name":"Department of Psychological Medicine, University Malaya, 50603 Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo-Ching Eileena","family":"Chui","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Queen Mary Hospital and KS Faculty of Medicine, University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnachai","family":"Kongsakon","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Mahidol University, 10400 Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Chin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of General Psychiatry, Taoyuan Psychiatric Center, 330053 Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0188-9449","authenticated-orcid":true,"given":"Chien-Heng","family":"Lin","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu County, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, 302645 Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beng Yeong","family":"Ng","sequence":"additional","affiliation":[{"name":"Ng Beng Yeong Psych Medicine Clinic, 329565 Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Wee Lun","family":"Tan","sequence":"additional","affiliation":[{"name":"Garden Grove Clinic, 427646 Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe Hang","family":"Ting","sequence":"additional","affiliation":[{"name":"Ting Specialist Clinic, 55100 Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meor Hakimi","family":"Meor Idris","sequence":"additional","affiliation":[{"name":"Marubeni Pharmaceuticals Malaysia, 50470 Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Keck PE Jr, McElroy SL, Arnold LM. Bipolar disorder. The Medical Clinics of North America. 2001; 85: 645\u201361, ix.","DOI":"10.1016\/s0025-7125(05)70334-5"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Bonn\u00edn CDM, Reinares M, Mart\u00ednez-Ar\u00e1n A, Jim\u00e9nez E, S\u00e1nchez-Moreno J, Sol\u00e9 B, et al. Improving Functioning, Quality of Life, and Well-being in Patients With Bipolar Disorder. The International Journal of Neuropsychopharmacology. 2019; 22: 467\u2013477.","DOI":"10.1093\/ijnp\/pyz018"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Teh WL, Abdin E, Vaingankar J, Shafie S, Yiang Chua B, Sambasivam R, et al. Prevalence and correlates of bipolar spectrum disorders in Singapore: Results from the 2016 Singapore Mental Health Study (SMHS 2016). Journal of Affective Disorders. 2020; 274: 339\u2013346.","DOI":"10.1016\/j.jad.2020.05.032"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Bartoli F, Bassetti C, Gazzola M, Gianfelice L, Cavaleri D, Crocamo C, et al. Prevalence and correlates of manic\/hypomanic and depressive predominant polarity in bipolar disorder: systematic review and meta-analysis. BJPsych Open. 2024; 10: e100.","DOI":"10.1192\/bjo.2024.51"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Moor S, Crowe M, Luty S, Carter J, Joyce PR. Effects of comorbidity and early age of onset in young people with Bipolar Disorder on self harming behaviour and suicide attempts. Journal of Affective Disorders. 2012; 136: 1212\u20131215.","DOI":"10.1016\/j.jad.2011.10.018"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet (London, England). 2016; 387: 1561\u20131572.","DOI":"10.1016\/S0140-6736(15)00241-X"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Kozloff N, Cheung AH, Schaffer A, Cairney J, Dewa CS, Veldhuizen S, et al. Bipolar disorder among adolescents and young adults: results from an epidemiological sample. Journal of Affective Disorders. 2010; 125: 350\u2013354.","DOI":"10.1016\/j.jad.2010.02.120"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"McGinty KR, Janos J, Seay J, Youngstrom JK, Findling RL, Youngstrom EA, et al. Comparing self-reported quality of life in youth with bipolar versus other disorders. Bipolar Disorders. 2023; 25: 648\u2013660.","DOI":"10.1111\/bdi.13320"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Arnold I, Dehning J, Grunze A, Hausmann A. Old Age Bipolar Disorder-Epidemiology, Aetiology and Treatment. Medicina (Kaunas, Lithuania). 2021; 57: 587.","DOI":"10.3390\/medicina57060587"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Depp CA, Jeste DV. Bipolar disorder in older adults: a critical review. Bipolar Disorders. 2004; 6: 343\u2013367.","DOI":"10.1111\/j.1399-5618.2004.00139.x"},{"key":"ref11","unstructured":"Sit D. Women and bipolar disorder across the life span. Journal of the American Medical Women's Association (1972). 2004; 59: 91\u2013100."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Abdelhafez MA, Ahmed KM, Ahmed NM, Ismail M, Mohd Daud MNB, Ping NPT, et al. Psychiatric illness and pregnancy: A literature review. Heliyon. 2023; 9: e20958.","DOI":"10.1016\/j.heliyon.2023.e20958"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Edinoff AN, Silverblatt NS, Vervaeke HE, Horton CC, Girma E, Kaye AD, et al. Hyperprolactinemia, Clinical Considerations, and Infertility in Women on Antipsychotic Medications. Psychopharmacology Bulletin. 2021; 51: 131\u2013148.","DOI":"10.64719\/pb.4396"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"McCormick U, Murray B, McNew B. Diagnosis and treatment of patients with bipolar disorder: A review for advanced practice nurses. Journal of the American Association of Nurse Practitioners. 2015; 27: 530\u2013542.","DOI":"10.1002\/2327-6924.12275"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Yalin N, Young AH. Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options? Neuropsychiatric Disease and Treatment. 2020; 16: 1459\u20131472.","DOI":"10.2147\/NDT.S245166"},{"key":"ref16","unstructured":"Singapore HSA. New drug indication approval - October 2021. 2021. Available at: https:\/\/www.hsa.gov.sg\/announcements\/new-drug-indication-approvals\/new-drug-indication-approval---october-2021 (Accessed: 13 February 2026)."},{"key":"ref17","unstructured":"Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma announces the approval of atypical antipsychotic Latuda (lurasidone HCl) for the treatment of patients with schizophrenia in China. 2019. Available at: https:\/\/www.sumitomo-pharma.com\/news\/20190129-2.html (Accessed: 13 February 2026)."},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Jaeschke RR, Sowa-Ku\u0107ma M, Pa\u0144czyszyn-Trzewik P, Misztak P, Stycze\u0144 K, Datka W. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile. Pharmacological Reports : PR. 2016; 68: 748\u2013755.","DOI":"10.1016\/j.pharep.2016.04.002"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Loebel A, Citrome L. Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. BJPsych Bulletin. 2015; 39: 237\u2013241.","DOI":"10.1192\/pb.bp.114.048793"},{"key":"ref20","unstructured":"Azhar Y, Shaban K. Lurasidone. StatPearls In StatPearls. Treasure Island (FL). 2025."},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. The American Journal of Psychiatry. 2014; 171: 169\u2013177.","DOI":"10.1176\/appi.ajp.2013.13070985"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. The American Journal of Psychiatry. 2014; 171: 160\u2013168.","DOI":"10.1176\/appi.ajp.2013.13070984"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Suppes T, Kroger H, Pikalov A, Loebel A. Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. Journal of Psychiatric Research. 2016; 78: 86\u201393.","DOI":"10.1016\/j.jpsychires.2016.03.012"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders. 2014; 155: 20\u201327.","DOI":"10.1016\/j.jad.2013.10.040"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Lin YW, Chen YCB, Hung KC, Liang CS, Tseng PT, Carvalho AF, et al. Efficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose-response meta-analysis. BMJ Mental Health. 2024; 27: e301165.","DOI":"10.1136\/bmjment-2024-301165"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders. 2018; 20: 97\u2013170.","DOI":"10.1111\/bdi.12609"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Cheng CM, Chang WH, Lin YT, Chen PS, Yang YK, Bai YM, et al. Taiwan consensus on biological treatment of bipolar disorder during the acute, maintenance, and mixed phases: The 2022 update. Asian Journal of Psychiatry. 2023; 82: 103480.","DOI":"10.1016\/j.ajp.2023.103480"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Fountoulakis KN, Grunze H, Vieta E, Young A, Yatham L, Blier P, et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines. The International Journal of Neuropsychopharmacology. 2017; 20: 180\u2013195.","DOI":"10.1093\/ijnp\/pyw109"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Keramatian K, Chithra NK, Yatham LN. The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence. Focus (American Psychiatric Publishing). 2023; 21: 344\u2013353.","DOI":"10.1176\/appi.focus.20230009"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology (Oxford, England). 2016; 30: 495\u2013553.","DOI":"10.1177\/0269881116636545"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. The Australian and New Zealand Journal of Psychiatry. 2015; 49: 1087\u20131206.","DOI":"10.1177\/0004867415617657"},{"key":"ref32","unstructured":"Malaysian Health Technology Assessment Section (MaHTAS). Clinical practice guidelines: management of bipolar disorder. 2nd edn. 2024. Available at: https:\/\/mymahtas2.moh.gov.my\/files\/eCPG%20BD2_24102025.pdf (Accessed: 11 March 2026)."},{"key":"ref33","unstructured":"Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, et al. The RAND\/UCLA Appropriateness Method User's Manual. RAND Corporation. 2001; 112."},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Maruki T, Utsumi T, Takeshima M, Fujiwara Y, Matsui M, Aoki Y, et al. Efficacy and safety of adjunctive therapy to lamotrigine, lithium, or valproate monotherapy in bipolar depression: a systematic review and meta-analysis of randomized controlled trials. International Journal of Bipolar Disorders. 2022; 10: 24.","DOI":"10.1186\/s40345-022-00271-7"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"McIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. The Journal of Clinical Psychiatry. 2015; 76: 398\u2013405.","DOI":"10.4088\/JCP.14m09410"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Chapel S, Chiu YY, Hsu J, Cucchiaro J, Loebel A. Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis. Clinical Therapeutics. 2016; 38: 4\u201315.","DOI":"10.1016\/j.clinthera.2015.11.013"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Sajatovic M, Forester BP, Tsai J, Kroger H, Pikalov A, Cucchiaro J, et al. Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies. The Journal of Clinical Psychiatry. 2016; 77: e1324\u2013e1331.","DOI":"10.4088\/JCP.15m10261"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"DelBello MP, Goldman R, Phillips D, Deng L, Cucchiaro J, Loebel A. Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study. Journal of the American Academy of Child and Adolescent Psychiatry. 2017; 56: 1015\u20131025.","DOI":"10.1016\/j.jaac.2017.10.006"},{"key":"ref39","unstructured":"Sumitomo Pharma Canada, Inc. Latuda (lurasidone hydrochloride tablets) product monograph. 2024. Available at: https:\/\/pdf.hres.ca\/dpd_pm\/00074299.PDF (Accessed: 13 February 2026)."},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Costamagna I, Calisti F, Cattaneo A, Hsu J, Tocco M, Pikalov A, et al. Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies. European Psychiatry : the Journal of the Association of European Psychiatrists. 2021; 64: e35.","DOI":"10.1192\/j.eurpsy.2021.30"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Sohn M, Burgess M, Bazzi M. Antipsychotic Polypharmacy among Children and Young Adults in Office-Based or Hospital Outpatient Department Settings. Pharmacy (Basel, Switzerland). 2017; 5: 64.","DOI":"10.3390\/pharmacy5040064"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Mole TB, Furlong Y, Clarke RJ, Rao P, Moore JK, Pace G, et al. Lurasidone for Adolescents With Complex Mental Disorders: A Case Series. Journal of Pharmacy Practice. 2022; 35: 800\u2013804.","DOI":"10.1177\/0897190021997011"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D. A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse. Schizophrenia Bulletin. 2021; 47: 1116\u20131129.","DOI":"10.1093\/schbul\/sbab017"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Cerovecki A, Musil R, Klimke A, Seem\u00fcller F, Haen E, Schennach R, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs. 2013; 27: 545\u2013572.","DOI":"10.1007\/s40263-013-0079-5"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M, et al. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy. Psychotherapy and Psychosomatics. 2017; 86: 189\u2013219.","DOI":"10.1159\/000477313"},{"key":"ref46","unstructured":"National Collaborating Centre for Mental Health (UK). Bipolar Disorder: The NICE Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. The British Psychological Society and The Royal College of Psychiatrists In The British Psychological Society and The Royal College of Psychiatrists. London. 2014."},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Kato T, Ishigooka J, Miyajima M, Watabe K, Fujimori T, Masuda T, et al. Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression. Psychiatry and Clinical Neurosciences. 2020; 74: 635\u2013644.","DOI":"10.1111\/pcn.13137"},{"key":"ref48","unstructured":"Sunovion Pharmaceuticals Inc. Latuda (lurasidone hydrochloride) tablets: highlights of prescribing information. 2013. Available at: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=88a244d1-eddb-499c-bee2-e1f49056e78f (Accessed: 13 February 2026)."},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Furukawa Y, Imai K, Takahashi Y, Efthimiou O, Leucht S. Comparative Efficacy and Acceptability of Treatment Strategies for Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-analysis. Schizophrenia Bulletin. 2026; 52: sbae098.","DOI":"10.1093\/schbul\/sbae098"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Lerner V, Bergman J, Statsenko N, Miodownik C. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 2004; 65: 1550\u20131554.","DOI":"10.4088\/jcp.v65n1118"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Kolli V, Walia A, Kinnan S. Food Matters: Reduction of Lurasidone-Induced Nausea With Meals. The Primary Care Companion for CNS Disorders. 2019; 21: 18l02343.","DOI":"10.4088\/PCC.18l02343"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Javed A, Arthur H, Curtis L, Hansen L, Pappa S. Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia. Neurology and Therapy. 2019; 8: 215\u2013230.","DOI":"10.1007\/s40120-019-0138-z"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, et al. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. The American Journal of Psychiatry. 2017; 174: 927\u2013942.","DOI":"10.1176\/appi.ajp.2017.16121358"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Kernizan N, Forinash A, Yancey A, Kruger S, Chavan NR, Mathews K. Mood stabilizers for treatment of bipolar disorder in pregnancy and impact on neonatal outcomes. Bipolar Disorders. 2024; 26: 779\u2013784.","DOI":"10.1111\/bdi.13481"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 5. Obstetrics and Gynecology. 2023; 141: 1262\u20131288.","DOI":"10.1097\/AOG.0000000000005202"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Wesseloo R, Kamperman AM, Munk-Olsen T, Pop VJM, Kushner SA, Bergink V. Risk of Postpartum Relapse in Bipolar Disorder and Postpartum Psychosis: A Systematic Review and Meta-Analysis. The American Journal of Psychiatry. 2016; 173: 117\u2013127.","DOI":"10.1176\/appi.ajp.2015.15010124"},{"key":"ref57","unstructured":"Cruz MP. Lurasidone HCl (Latuda), an Oral, Once-Daily Atypical Antipsychotic Agent for the Treatment of Patients with Schizophrenia. P & T : a Peer-reviewed Journal for Formulary Management. 2011; 36: 489\u2013492."},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Betcher HK, Montiel C, Clark CT. Use of Antipsychotic Drugs During Pregnancy. Current Treatment Options in Psychiatry. 2019; 6: 17\u201331.","DOI":"10.1007\/s40501-019-0165-5"},{"key":"ref59","unstructured":"Food and Drug Administration, HHS. Content and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for Pregnancy and Lactation Labeling. 2014. Available at: https:\/\/www.federalregister.gov\/documents\/2014\/12\/04\/2014-28241\/content-and-format-of-labeling-for-human-prescription-drug-and-biological-products-requirements-for (Accessed: 13 February 2026)."},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Montiel C, Newmark RL, Clark CT. Perinatal use of lurasidone for the treatment of bipolar disorder. Experimental and Clinical Psychopharmacology. 2022; 30: 249\u2013252.","DOI":"10.1037\/pha0000509"},{"key":"ref61","unstructured":"Malaysian Health Technology Assessment Section (MaHTAS). Clinical Practice Guidelines: Management of Bipolar Disorder in Adults. 2014. Available at: https:\/\/psychiatry-malaysia.com\/wp-content\/uploads\/2022\/01\/20151019CPG_Management_of_Bipolar_Disorder_in_Adults.pdf (Accessed: 11 March 2026)."}],"container-title":["Alpha Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/AP\/27\/3\/10.31083\/AP49358","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:44:03Z","timestamp":1783428243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/AP\/27\/3\/10.31083\/AP49358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2757-8038(26)02183-X"],"URL":"https:\/\/doi.org\/10.31083\/ap49358","relation":{},"ISSN":["2757-8038"],"issn-type":[{"value":"2757-8038","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"49358"}}